Published:
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals,
Inc. (Nasdaq: ALSE), today announced that they will host a conference call on
Thursday, May 15th, 2008 at 9:00am EDT to review the first quarter ending
March 31, 2008 and discuss other matters related to the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
To access the conference call, please dial 877-795-3649 for domestic and
719-325-4817 international. The code for this conference call is 1073493.
Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of
the call will be posted on the Investor Relations section of our website,
www.alseres.com, within 48 hours following the conference call and will be
available through Thursday, May 29th, 2008.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company's
focus is reflected in several important initiatives. Cethrin, a
recombinant-protein-based drug designed to promote nerve repair after acute
spinal cord injury, demonstrated positive interim results in a Phase I/IIa
clinical trial. The Company's research and pre-clinical programs include,
Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for
the treatment of ocular injury and disease and research programs directed at a
number of regenerative therapies including bone repair. The Company has a
robust molecular imaging development program targeting diagnosis of
Parkinson's disease and potentially dementia. The Company's lead molecular
imaging product candidate is Altropane which is in Phase III clinical trials
for the diagnosis of Parkinsonian Syndromes including Parkinson's disease.
The Company has research collaborations with Harvard Medical School and
Children's Hospital Boston.
Forward-Looking Statements
The foregoing release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements include statements regarding Alseres' future
expectations, beliefs, intentions, goals, strategies, plans or prospects
regarding the future, including the development and commercialization of
Altropane and Cethrin, the prospects of the Company's CNS and regenerative
therapeutics programs, the Company's strategies to develop and commercialize
axon regeneration technologies and the breadth of the Company's technologies
and intellectual property portfolio. Forward-looking statements can be
identified by terminology such as "anticipate," "believe," "could," "could
increase the likelihood," "estimate," "expect," "intend," "is planned," "may,"
"should," "will," "will enable," "would be expected," "look forward," "may
provide," "would" or similar terms, variations of such terms or the negative
of those terms. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors including those risks, uncertainties
and factors referred to in the Company's Annual Report on Form 10-K for the
year ended December 31, 2007 filed with the Securities and Exchange Commission
under the section "Risk Factors," as well as other documents that may be filed
by Alseres from time to time with the Securities and Exchange Commission. As
a result of such risks, uncertainties and factors, the Company's actual
results may differ materially from any future results, performance or
achievements discussed in or implied by the forward-looking statements
contained herein. Alseres is providing the information in this press release
as of this date and assumes no obligations to update the information in this
press release.
Alseres is a trademark and Cethrin and Altropane are registered trademarks
of Alseres Pharmaceuticals, Inc.
Contact:
Sharon Correia - 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc.
scorreia@alseres.com
Adam Friedman - 212-981-2529 ext. 18
Adam Friedman Associates
adam@adam-friedman.com
SOURCE Alseres Pharmaceuticals, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Tags: Healthcare, Pharmaceuticals, Banking and Finance, Health, , massachusetts
_ _
Search News
Daily News
